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1. Introduction 
The Alzheimer’s disease (AD) is the most frequent form of dementia worldwide. The major 
neuropathological hallmarks of the disease are loss of neurons and synapse, senile plaques 
(extracellular aggregates primarily composed of ß-amyloid; Aß) and neurofibrillary tangles 
(aggregates of hyperphosphorylated forms of the microtubule-associated tau protein) 
throughout cortical and limbic regions of the brain. The definite diagnosis still requires 
histopathological conformation according to the criteria, however, in recent years 
substantial progress has been made in the area of early biomarker development. The use of 
cerebrospinal fluid as a testing platform is very promising because the CSF protein 
composition can reflect the pathological processes of the brain and because it is easily 
accessible by a lumbar puncture. Some proteins and peptides such as ß-amyloid 1-42 (Aǃ1-
42), ß-amyloid 1-40 (Aǃ1-40), total tau (tau) and hyperphosphorylated tau (p-tau) have been 
reported to meet the criteria for a biomarker. Another series of publications reported 
transthyretin, isoprostane, BACE1 activity and other proteins and enzymes as a potential 
biomarkers in AD.  Whereas the biomarkers mentioned first have been studied extensively 
and were suggested to be included into clinical AD criteria, less information is available on 
the others. This review will focus on the importance of CSF based biomarkers in AD, covers 
the data available from the literature and highlights their role in the differential diagnosis of 
dementia. 
2. Why to use CSF as a testing platform in dementia? ─ Neuroanatomy driven 
approach 
Cerebrospinal fluid (CSF) is the main component of the brain extracellular space and 
participates in the exchange of many biochemical products in the central nervous system 
(CNS). Consequently, CSF contains a dynamic and complex mixture of proteins, which 
reflects physiological or pathological state of CNS. Changes in CSF proteome have been 
described in various neurodegenerative disorders. These alterations are discussed to reflect 
pathological changes in the brain and thus contribute to a better understanding of the 
pathophysiology of the underlying disorder (Gawinecka et al. 2010). 
CSF analysis is extremely important to identify autoimmune disorders and inflammatory 
conditions, which might lead to dementia. Although changes are non-specific, like 
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pleocytosis, elevated protein content, increased albumin ratio and oligoclonal IgG synthesis 
within the central nervous system, their presence clearly differentiate inflammatory and 
autoimmune disease from neurodegenerative dementia.  
3. How to select a biomarker ─ a concept-of-pathogenesis-driven approach 
Several potential biomarkers in the CSF and blood have been already suggested. Some of 
them like Aǃ1-42 and tau (and its phosphorylated form) became important biomarker in 
dementia diagnosis. The advantage of these biomarkers is their clear link to the pathological 
process and abnormalities, which are detected in the brain of AD patients (Aß and amyloid 
hypothesis as well as tau pathology). 
3.1 Amyloid hypothesis 
The amyloid core of senile or neuritic plaques contains an amyloid-like substance formed by 
peptides, which originate from proteolytic cleavage of the membrane-associated precursor 
protein (amyloid precursor protein, APP). They are generated by a sequential cleavage of 
amyloid precursor protein (APP) by ǃ- and Ǆ-secretase. Aǃs are small hydrophobic peptides 
existing mainly in two lengths: Aǃ1-40 and Aǃ1-42. It was initially assumed that the 
production of Aǃs occurs only under pathological conditions. Later, Aǃ was shown to be 
constitutively released from APP and secreted to blood and CSF. In AD, Aǃ peptides are 
involved in pathological processes and accumulate in the brain as amyloid or senile plaques. 
There is clear correlation between Aǃ levels in CSF and plaque depositions in the brain 
coupled with the concept of casual involvement of APP and Aǃs in the pathogenesis of AD. 
The concentration of Aǃs is thought to reflect disease-associated changes and is widely 
applied as a diagnostic biomarker of AD (Gawinecka et al. 2010).  
Table 1 gives an overview of publications related to this topic from past 5 years. The vast 
majority of publications is related to the detection of abnormal levels of Aß1-42 in AD as 
compared to other dementia, however, some data are also available for Aß1-40. Recently, a 
ratio between both peptides has been suggested as a potential biomarker in AD (Table 2). 
Aß1-42 level is decreased in patients with AD, but might also decrease in other dementia, 
too. Test sensitivity for Aß1-42 alone is given from 60 to 96%, depending on the design of 
the study. 
In MCI, Aß42 level is lower in patients with a subsequent AD diagnosis (De Meyer et al. 
2010; Diniz et al. 2008; Mattsson et al. 2009; Stefani et al. 2006), which leads to the conclusion 
that this parameter might also serve as an preclinical (potential predictive?) biomarker 
(Stefani et al. 2006) for cognitive decline. 
Aß42 level is decreased in other conditions, including prion diseases, Parkinson’s disease 
(Siderowf et al. 2010) and DLB. In PD, decreased levels correlate well with cognitive decline, 
in contrast to tau/p-tau ratio (see below) (Siderowf et al. 2010). According to some studies 
which used patients with non-AD dementia as controls, this marker is highly sensitive for 
detection of dementia, but it seems that it does not allow to discriminate between various 
dementia types because of limited  specificity (Formichi et al. 2006; Gloeckner et al. 2008).  
One approach to improve test sensitivity and specificity was to calculate an Aß42/40 ratio, 
which is significantly decreased in AD patients. It seems also to discriminate between 
different dementia including AD and non-AD (vascular, mixed, FTD, alcohol toxic and 
controls) (Lewczuk et al. 2004). However, the significance of this finding has still to be 
proven on higher numbers of patients in a prospective study. 
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 Patients (n) Sensitivity (%) Specificity (%) Reference 
Aß1-42 MCI -> AD (422) 
controls (429) 
68 93 (Diniz et al. 2008) 
Aß1-42 PD (109) 
AD (20) 
controls (36) 
n.a. (Alves et al. 2010) 
Aß1-42 AD (131) 
controls (72) 
92 89 (Sunderland et al. 
2003) 
Aß1-42 PD (45) n.a. (Siderowf et al. 
2010) 
Aß1-42 MCI n.a. (Okonkwo et al. 
2011) 
Aß1-42 AD (33) 
ARCD* (20) 
controls (50) 
70-84 80-85 (Kapaki et al. 
2005) 
Aß1-42 MCI (750) 
AD (529) 
controls (304) 
79 65 (Mattsson et al. 
2009) 
Aß1-42 autoptic AD (68) 
MCI (57) 
94 n.a. (De Meyer et al. 
2010) 
Aß1-42 AD >85 >85 (Slats et al. 2010) 
Aß1-42 mild AD (100) 
MCI (196) 
controls (114) 
96 77 (Shaw et al. 2009) 
Aß1-40 AD (82) 
DLB (44) 
controls (71) 
AD vs controls 
97 




Aß1-40 DLB (21) 
AD (23) 
PDD (21) 













61 78 (Gloeckner et al. 
2008) 
*ARCD = alcohol related cognitive disorder 
 
Table 1. Aß40 and Aß42 in dementia diagnosis 
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 Diagnosis (n) Sensitivity (%) Specificity (%) Reference 
Aß1-42/ 
Aß1-40 
MCI (65) 86 60 (Brys et al. 2009) 
Aß1-42/ 
Aß1-40 








AD (69)   (Spies et al. 2010) 
Aß1-42/ 
Aß1-40 
AD (18) AD vs control: 100 
AD vs DLB: 100 
AD vs both groups: 
100 
AD vs control: 93 
AD vs DLB: 68 
AD vs both groups: 77 
(Bibl et al. 2006b) 
Aß1-42/ 
Aß1-40 
AD (109) AD vs control: 79 
AD vs all: 70 
AD vs control: 71 
AD vs all: 71 
(Brettschneider et 
al. 2006) 
Table 2. Aß1-42/ Aß1-40 ratio as potential biomarkers in AD 
3.2 Tau hypothesis 
Intracellular neurofibrillary tangles (NFT), which are neuronal inclusions consisting of 
abnormal cytoskeletal elements of hyperphosphorylated tau protein are another 
characteristic pathological feature of AD. These tangles are found throughout the neocortex, 
in the nucleus basalis Meynert, thalamus, and in the mammillary bodies. Tau protein is a 
microtubule-associated protein (MAP), which interacts with tubulin and promotes 
microtubule assembly and stability; it is also involved in neurogenesis, axonal maintenance 
and axonal transport. There are six different tau isoforms present in the human adult brain, 
which are generated by an alternative mRNA splicing from a single gene (Goedert et al. 
1989). Tau is a phosphoprotein, with 79 putative serine or threonine phosphorylation sites 
on the longest tau isoform. The hyperphosphorylated tau has a reduced affinity for 
microtubules and reduced ability to promote their assembly (Lindwall and Cole 1984). In 
AD, tau detaches from microtubules and aggregates in paired helical filaments (PHFs). Tau 
isolated from these aggregates is found to be about 4 times more phoshorylated than tau 
isolated from nondemented individuals (Alonso et al. 2001; Kopke et al. 1993, Gawinecka 
and Zerr 2010).  
The elevated CSF level of nonphosphorylated and phosphorylated tau is one of AD 
hallmarks (Andreasen et al. 1999; Arai et al. 1997; Galasko et al. 1997; Ishiguro et al. 1999; 
Itoh et al. 2001; Mecocci et al. 1998). Since the first description of this abnormality and 
availability of an ELISA test, extensive research has been conducted. Data on tau level in AD 
and other dementia are given in Table 3. Again, elevated levels can be observed in other 
conditions than AD too, the test sensitivity and specificity seems to be above 80% in 
majority of the cases (Table 3). However, it has to be kept in mind that tau levels increase in 
CSF with age and this physiological finding hast to be kept in mind when cut-off level are 
established (Figure 1). In pathological conditions, total tau levels in MCI patients indicate 
increased AD risk (Hertze et al. 2010; Mattsson et al. 2009; Pauwels et al. 2009) and increased 
level correlates well with disease severity (Buchhave et al. 2009; Stefani et al. 2006). Some 
studies even demonstrated that extremely high tau levels might be indicator of poor 
prognosis (Snider et al. 2009).  
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Patients (n) Sensitivity (%) Specificity (%) Reference 
MCI (166) 78 83 (Hertze et al. 2010) 
AD (131) 92 89 (Sunderland et al. 2003) 
AD, CJD, LBD, 
FTD, VD 
73-91 74-98 (van Harten et al. 2011) 
AD (33) 
ARCD* (20) 
88-94 95-96 (Kapaki et al. 2005) 
AD 
NPH 
91-93 78-96 (Kapaki et al. 2007) 
MCI (750) 
AD (529) 




88 80 (Ibach et al. 2006) 
early AD (269) 
mild AD (468) 
late AD (495) 
n.a. (Stefani et al. 2006) 
MCI -> AD 82 87 (Pauwels et al. 2009) 
mild AD (100) 
MCI (192) 
autoptic AD (56) 
controls (114) 
70 92 (Shaw et al. 2009) 
MCI -> AD (422) 
controls (420) 
68 93 (Diniz et al. 2008) 
DLB (34) 
AD (31) 
other dementia (4) 
85 95 (Kasuga et al. 2010) 
*ARCD = alcohol related cognitive disorder 
Table 3. Total tau level in cerebrospinal fluid in AD and other dementia 
Regarding phosphorylated tau level in CSF, a recent metaanalysis on 51 publications from 
the area revealed that p-tau contributed to the separation of MCI from healthy individuals 
with a sensitivity of 80% and specificity of 84% (Mitchell 2009). CSF p-tau is a good 
diagnostic biomarker of AD too, with test sensitivity mostly >80% (see Table 4). MCI 
patients with low Aß1-42 and high p-tau levels are at a clear AD risk (Hertze et al. 2010). AD 
patients with higher p-tau level have greater hippocampal atrophy, poorer 
neuropsychological test results and it is also indicator of disease progression (Henneman et 
al. 2009). Whereas p-tau levels indicate AD or development of AD with good accuracy, 
unfortunately, this biomarker is also less adequate in separating AD from other dementias 
(Mitchell 2009).  
Due to these considerations, several studies tried to analyse the diagnostic potential of p-
tau/total tau ratio. Some of them reported test sensitivity between 88-96% with a specificity 
of 60-100%. While its ratio is promising, again, it has to be analysed in a prospective setting 
since the numbers of analysed patients so far are too low for any definite conclusions 
(Buerger et al. 2006; Hu et al. 2002; Kapaki et al. 2007). 
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Fig. 1. Total tau level in cerebrospinal fluid stratified by age in healthy controls (Gloeckner 
et al. 2008) 
 




>85 79-91 (Scheurich et 
al. 2010) 




>85 79-91 (Hertze et al. 
2010) 
p-tau AD (49) 46 94 (Snider et al. 
2009) 
p-tau AD (251) 
controls (122) 
62 93 (Formichi et al. 
2006) 
p-tau AD, CJD, LBD, 
FTD, vascular 
dementia 
79-88 78-83 (van Harten et 
al. 2011) 
p-tau AD, NPH, controls 89 87 (Kapaki et al. 
2007) 




89 87 (Ibach et al. 
2006) 
p-tau AD (31) 
MCI (25) 




Cerebrospinal Fluid Based Diagnosis in Alzheimer’s Disease 
 
213 
 Patients (n) Sensitivity (%) Specificity (%) Reference 




 (De Meyer et 
al. 2010) 
p-tau mild AD (100) 
MCI (196) 
autoptic AD (56) 
controls (114) 
68 73 (Shaw et al. 
2009) 
p-tau MCI (750) 
AD (529) 
Controls (304) 
84 47 (Mattsson et al. 
2009) 
p-tau/total tau AD (52) 
controls (56) 
non AD (37) 
vascular dementia 
(46) 
96 94 (Hu et al. 2002) 
p-tau/total tau AD (67) 
NPH (18) 
controls (72) 
88-93 60-100 (Kapaki et al. 
2007) 
p-tau/total tau AD (37) 
CJD (21) 
controls (10) 
91 97 (Buerger et al. 
2006) 




ratio AD: 1,27 (mean) 
ratio FTD: 1,13 (mean) 
ratio CJD: 0,05 (mean) 
ratio controls: 1,7 (mean) 
(Riemenschnei
der et al. 2003) 




86 90 (Bahl et al. 
2009) 
Table 4. Phosphorylated tau level in cerebrospinal fluid in AD and other dementia 
In general, many studies on Aß1-42, total tau level and its phosphorylated isoform have 
been performed. In most studies, the number of patients per group is limited and various 
criteria and diagnostic techniques have been applied. Of importance, a recent multicenter 
study demonstrated once again that CSF Aß1-42, total tau and p-tau identify incipient AD 
with good sensitivity and specificity, however, the data are less reliable than reported from 
single-center studies (Mattsson et al. 2009). Thus, improvements are necessary, with respect 
to standardisation protocols between centers, but also with respect to identification of 
further disease- specific biomarkers in biological fluids. 
3.3 The role of ApoE  
The presence of the apolipoprotein E allele is a well documented risk factor for AD (Lamb et 
al. 1998; Saunders et al. 1993) and is associated with a decreased age of clinical onset, with a 
higher stage of ß-amyloid deposition and neurofibrillary change formation, severe disease 
course, higher brain atrophy and a more rapid disease course (Ohm et al. 1999). The ApoE 
polymorphism includes three common alleles (ε2, ε3, ε4) at a single gene locus resulting in 
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six ApoE genotypes ε2/ε2, ε3/ε3, ε4/ε4, ε2/ε3, ε2/ε4, ε3/ε4. The ApoE ε4 allele is an 
established risk factor for AD (Saunders et al. 1993) and there is a large body of evidence for 






Influence of ApoE ε4 allele Reference 
Aß1-42 82 dose-dependent reduction (Galasko et al. 1998) 
tau heterozygous: elevation 
homozygous: reduction 
 
Aß1-42 50 dose-dependent reduction (Riemenschneider et al. 
2000) 
Aß1-42 84 dose-dependent reduction (Hulstaert et al. 1999) 
Aß1-42 73 more reduced levels in ε4 
carriers 
(Smach et al. 2008) 
tau no influence  
Aß1-42 60 no influence (Ewers et al. 2008) 
Aß1-42 50 no influence (Engelborghs et al. 2007) 
tau  no influence  
tau 19 dose-dependent elevation (Golombowski et al. 1997) 
Aß1-42 121 [41 NP] more reduced levels in ε4 
carriers 
(Tapiola et al. 2000) 
tau more elevated levels in ε4 
carriers 
 
Aß1-42 563 more reduced levels in ε4 
carriers 
(Prince et al. 2004) 
Aß1-42 150 more reduced levels in ε4 
carriers 
(Sunderland et al. 2004) 
 
Table 5. Influence of the ApoE ε4 allele on CSF markers in AD (modified from Varges et al. 
2011) 
The ApoE ε4 allele status is important to be analysed in the context of CSF biomarker.  Some 
studies report no association between ApoE ε4 allele and tau level, whereas others show 
higher tau level among ApoE ε4 carriers when compared to non-carriers among AD 
patients.  The situation seems to be clearer for ß-amyloid 1-42: several studies report 
correlations between Aß1-42 levels and the ApoE ε4 allele (Table 5) (modified from Varges et 
al. 2011). Although the pathological links are not clearly identify at the moment, it is 
apparent that the ApoE genotype has to be taken into consideration. 
www.intechopen.com
 
Cerebrospinal Fluid Based Diagnosis in Alzheimer’s Disease 
 
215 
4. Clinical criteria for AD 
CSF biomarkers play an important role in clinical diagnosis and differential diagnosis of 
neurodegenerative dementia. A lot of research in this area has been already conducted. 
Recently, these markers which are associated with disease pathology in the brain namely 
Aß1-42 as a parameter of the amyloid cascade and tau and its phosphorylated isoforms 
have been suggested to be included into diagnostic criteria for AD. The typical AD 
signature comprises low CSF Aß1-42 levels and high total tau/p-tau level and it was 
suggested as a parameter of one of the supportive features at the same level as structural 
and functional brain imaging for probable AD diagnosis (Dubois et al. 2007). 
5. Conclusions 
The PubMed search on 31.1.2011 using keywords cerebrospinal fluid and Alzheimer reveals 
2336 hits. Although not all are dealing directly with biomarker discovery and identification 
of novel proteins for diagnosis, they are linked to the topic and demonstrate once again the 
importance of the area. Adequate biomarker, which can be easily analysed in CSF and, even 
better, blood, will have a great potential for clinical and also preclinical diagnosis of the 
disease. In neurodegenerative disorders, we have to meet the problem of early disease 
diagnosis, because it is likely that neuroprotective and other pharmacological strategies will 
allow better treatment response in earlier disease stages. 
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